Enzo Biochem, Inc. (ENZ) |
| 0.3138 -0.02 (-6.08%) 04-17 16:00 |
| Open: | 0.3702 |
| High: | 0.4 |
| Low: | 0.3138 |
| Volume: | 4,123,861 |
| Market Cap: | 16(M) |
| PE Ratio: | -2.24 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 1.27 |
| 52w Low: | 0.25 |
Enzo Biochem, Inc. is a diversified enterprise that encompasses diagnostics, clinical laboratory services, and life sciences. The company's core activities involve the entire process of researching, developing, manufacturing, and commercializing diagnostic and scientific investigation products, drawing upon advancements in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division is responsible for creating, producing, and distributing vital tools and reagents tailored for customers in clinical research, pharmaceutical development, and broader bioscience research. Its extensive product catalog features items such as proteins, antibodies, peptides, small molecules, labeling agents, dyes, and various kits. These offerings provide life science researchers with the means for target identification and validation, content analysis, gene expression studies, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also supplies specialized solutions to scientific experts investigating critical health areas, including cancer, cardiovascular ailments, neurological disorders, metabolic conditions (like diabetes and obesity), endocrine imbalances, infectious and autoimmune diseases, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment delivers a comprehensive spectrum of molecular and other clinical laboratory tests and procedures. These are utilized by physicians in routine patient care to help confirm or establish diagnoses, monitor the effectiveness of treatments or medications, and identify previously undiagnosed medical conditions. This division operates a central, full-service clinical laboratory in Farmingdale, New York, complemented by a network of 30 patient service centers across New York and New Jersey. Additionally, it runs dedicated "STAT" or rapid-response laboratories in New York City and Connecticut, alongside a full-service phlebotomy facility and an internal logistics department. The Therapeutics segment is dedicated to pioneering novel treatment approaches within the fields of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem distributes its array of products and services through its dedicated internal sales team and an extensive network of distributors, reaching both domestic and international markets. The company was established in 1976 and has its corporate headquarters situated in New York, New York.
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Sun, 05 Jul 2026
If You Invested $1,000 in Enzo Biochem Inc (ENZ) - Stock Titan
Mon, 24 Jul 2023
Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp - GlobeNewswire
Wed, 14 Jun 2023
Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results - GlobeNewswire
Fri, 04 Dec 2020
Enzo Biochem Stock Price Forecast. Should You Buy ENZ? - StockInvest.us
Tue, 19 Apr 2016
ENZ: Enzo Biochem, Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Tue, 04 May 2010
USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis - Nature
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |